FRAX(R) and its applications to clinical practice
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK. Bone
(Impact Factor: 3.97).
03/2009; 44(5):734-43. DOI: 10.1016/j.bone.2009.01.373
The introduction of the WHO FRAX algorithms has facilitated the assessment of fracture risk on the basis of fracture probability. FRAX integrates the influence of several well validated risk factors for fracture with or without the use of BMD. Its use in fracture risk prediction poses challenges for patient assessment, the development of practice guidelines, the evaluation of drug efficacy and reimbursement, as well as for health economics which are the topics outlined in this review.
Available from: Guowei Li
- "These findings were also consistent with the main results using the whole population (Table 2), implying no significant effect of the baseline anti-osteoporotic treatment and/or supplementation on the prediction of FRAX and FI in major osteoporotic fracture. Some studies argued that previous falls should be included into FRAX, since previous falls were an independent and significant risk factor for future fractures  . Nevertheless, evidence showed that models incorporating falls as a risk factor may not be superior to FRAX alone in predicting future risk of fractures . "
[Show abstract] [Hide abstract]
ABSTRACT: A frailty index (FI) of deficit accumulation could quantify and predict the risk of fractures based on the degree of frailty in the elderly. We aimed to compare the predictive powers between the FI and the fracture risk assessment tool (FRAX) in predicting risk of major osteoporotic fracture (hip, upper arm or shoulder, spine, or wrist) and hip fracture, using the data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) 3-year Hamilton cohort. There were 3,985 women included in the study, with the mean age of 69.4 years (standard deviation [SD] = 8.89). During the follow-up, there were 149 (3.98%) incident major osteoporotic fractures and 18 (0.48%) hip fractures reported. The FRAX and FI were significantly related to each other. Both FRAX and FI significantly predicted risk of major osteoporotic fracture, with a hazard ratio (HR) of 1.03 (95% confidence interval [CI]: 1.02-1.05) and 1.02 (95% CI: 1.01-1.04) for per-0.01 increment for the FRAX and FI respectively. The HRs were 1.37 (95% CI: 1.19 - 1.58) and 1.26 (95% CI: 1.12 - 1.42) for an increase of per-0.10 (approximately one SD) in the FRAX and FI respectively. Similar discriminative ability of the models was found: c-index = 0.62 for the FRAX and c-index = 0.61 for the FI. When cut-points were chosen to trichotomize participants into low-risk, medium-risk and high-risk groups, a significant increase in fracture risk was found in the high-risk group (HR = 2.04, 95% CI: 1.36-3.07) but not in the medium-risk group (HR = 1.23, 95% CI: 0.82-1.84) compared with the low-risk women for the FI, while for FRAX the medium-risk (HR = 2.00, 95% CI: 1.09-3.68) and high-risk groups (HR = 2.61, 95% CI: 1.48-4.58) predicted risk of major osteoporotic fracture significantly only when survival time exceeded 18 months (550 days). Similar findings were observed for hip fracture and in sensitivity analyses. In conclusion, the FI is comparable with FRAX in the prediction of risk of future fractures, indicating that measures of frailty status may aid in fracture risk assessment and fracture prevention in the elderly. Further evidence from randomized controlled trials of osteoporosis medication interventions is needed to support the FI and FRAX as validated measures of fracture risk.
Copyright © 2015. Published by Elsevier Inc.
Bone 04/2015; 77. DOI:10.1016/j.bone.2015.04.028 · 3.97 Impact Factor
Available from: Laura D'Erasmo
- "A growing attention is paid to test the predictive capacity of algorithms based on clinical risk factors, among which the FRAX tool is the most diffused worldwide. It predicts the ten-year probability of either major osteoporotic (a composed endpoint of femur, spine, humerus and forearm fractures) or hip fracture . Noteworthy, T2DM is not included among the primary entry variables of FRAX. "
[Show abstract] [Hide abstract]
ABSTRACT: This review focuses on the mechanisms determining bone fragility in patients with type 2 diabetes mellitus (T2DM). Despite bone mineral density (BMD) is usually normal or more often increased in these patients, fracture incidence is high, probably because of altered bone "quality". The latter seems to depend on several, only partly elucidated, mechanisms, such as the increased skeletal content of advanced glycation end-products causing collagen deterioration, the altered differentiation of bone osteogenic cells, the altered bone turnover and micro-architecture. Disease duration, its severity and metabolic control, the type of therapy, the presence or absence of complications, as like as the other known predictors for falls, are all relevant contributing factors affecting fracture risk in T2DM. In these patients the estimate of fracture risk in the everyday clinical practice may be challenging, due to the lower predictive capacity of both BMD and risk factors-based algorithms (e.g. FRAX).
Nutrition Metabolism and Cardiovascular Diseases 11/2014; DOI:10.1016/j.numecd.2014.06.013. · 3.32 Impact Factor
Available from: Jung Hee Koh
- "Giving the same weighted value for patients who took different dose of glucocorticoid it was inappropriate for the assessment of osteoporotic fracture risk. A recent study suggested the guideline for the adjustment of the FRAX model to the dose of glucocorticoids (25, 26). According to that study, the probability of major fractures decreased by about 20%, depending on age in cases of low dose exposure (<2.5 mg prednisolone daily or equivalent). "
[Show abstract] [Hide abstract]
ABSTRACT: The aim of the current study is to identify patients without osteoporosis who met the criteria of the fracture risk assessment tool (FRAX) of the National Osteoporosis Foundation (NOF) only. The incidence of fractures was investigated in patients who met only the FRAX criteria of the NOF and patients who presented osteoporosis. Five hundred and forty five patients with rheumatoid arthritis who visited a single center were recruited in Korea. In the follow-up period of median 30 months, the new onset of fractures was investigated. Of 223 patients who have no osteoporosis, 39 (17.4%) satisfied the FRAX criteria for pharmacological intervention. During the follow-up period, 2 new onset fractures occurred in patients who met only the FRAX criteria and 22 new onset fractures did in patients with osteoporosis by bone mineral density. The incidence rate for new onset fractures of patients who met only the FRAX criteria was with 295.93 per 10,000 person-years higher than in the general population with 114.99 per 10,000 person-years. Patients who met the FRAX criteria of the NOF only need pharmacological intervention because their numbers of incidence for new onset fractures are similar to those of patients with osteoporosis by BMD.
Journal of Korean Medical Science 08/2014; 29(8):1082-9. DOI:10.3346/jkms.2014.29.8.1082 · 1.27 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.